Sumanta Kumar Pal, M.D.

  • Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
  • Co-director, Kidney Cancer Program
  • Medical Oncologist

Sumanta Kumar Pal, M.D.

Clinical Specialties
  • Medical Oncology
Areas of Expertise
  • Urology and Urologic Oncology
  • Prostate Cancer
  • Bladder Cancer
  • Kidney Cancer
Research Focus
  • Urology and Urologic Oncology
Other Languages Spoken
  • Spanish
Sumanta (Monty) Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.

Dr. Pal entered college at the age of 13 and began medical school at University of California, Los Angeles at the age of 17. After completing his residency training at University of California, Los Angeles, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he remains on faculty since 2009.

Over that span of time, he has published more than 150 peer-reviewed articles that have been featured in prominent journals including The Journal of Clinical Oncology, Lancet Oncology, Cancer Cell, and European Urology.

Dr. Pal holds patents for new drugs currently under development in prostate cancer and also maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the west coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at Beckman Research Institute of City of Hope and urologists in the Department of Surgery. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for our currently incurable diseases. He has also worked to push the boundaries of personalized medicine in genitourinary cancers, with several seminal publications in rare genitourinary cancers that describe unique therapeutic targets.
Dr. Pal sits on the Editorial Board for clinical genitourinary cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others. Dr. Pal has received grants from the National Institute of Health, the Comprehensive Cancer Network, the Southwest Oncology Group, and multiple other leading entities in support of his formidable research.
  • 2009 - present, Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2009 - present, Co-director, Kidney Cancers Program, City of Hope, Duarte, CA
  • Bladder Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Testicular Cancer
  • Urology and Urologic Cancers


1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673


  • 2003, David Geffen School of Medicine at UCLA, Los Angeles, CA, M.D.
  • 1998, California State University, Los Angeles Early Entrance Program, College in lieu of high school (program initiated at age 13), Magna Cum Laude, B.Sc.


  • 2006 - 2009, Fellowship in Hematology/Oncology, City of Hope/Harbor-UCLA Medical Center, Los Angeles, CA


  • 2003 - 2006, Residency in Internal Medicine, UCLA Medical Center, Los Angeles, CA
The Perfect Marriage of Patient Care and Scientific Research
The Perfect Marriage of Patient Care and Scientific Research

Dr. Pal - Connecting Patient Care with Scientific Research

March 31, 2017

Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy.

  • 2006-present, American Society of Clinical Oncology (ASCO) (2006- present)
  • National Comprehensive Cancer Network Bladder Cancer Committee (2010-present)
  • HER2-Positive Breast Cancer Committee, ASCO (2012-2013)
  • Genitourinary Cancers Committee, ASCO (2013-present )
Back To Top